Cargando…

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on da...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Briasoulis, Alexandros, Gumeni, Sentiljana, Malandrakis, Panagiotis, Fotiou, Despina, Papanagnou, Eleni-Dimitra, Migkou, Magdalini, Theodorakakou, Foteini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Trougakos, Ioannis P., Kastritis, Efstathios, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327056/
https://www.ncbi.nlm.nih.gov/pubmed/34341335
http://dx.doi.org/10.1038/s41408-021-00530-3
_version_ 1783731986406309888
author Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Briasoulis, Alexandros
Gumeni, Sentiljana
Malandrakis, Panagiotis
Fotiou, Despina
Papanagnou, Eleni-Dimitra
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Kanellias, Nikolaos
Trougakos, Ioannis P.
Kastritis, Efstathios
Dimopoulos, Meletios A.
author_facet Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Briasoulis, Alexandros
Gumeni, Sentiljana
Malandrakis, Panagiotis
Fotiou, Despina
Papanagnou, Eleni-Dimitra
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Kanellias, Nikolaos
Trougakos, Ioannis P.
Kastritis, Efstathios
Dimopoulos, Meletios A.
author_sort Terpos, Evangelos
collection PubMed
description Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and MGUS (n = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 (p = 0.009) and on day 50 (p = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders.
format Online
Article
Text
id pubmed-8327056
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83270562021-08-02 The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment Terpos, Evangelos Gavriatopoulou, Maria Ntanasis-Stathopoulos, Ioannis Briasoulis, Alexandros Gumeni, Sentiljana Malandrakis, Panagiotis Fotiou, Despina Papanagnou, Eleni-Dimitra Migkou, Magdalini Theodorakakou, Foteini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Kanellias, Nikolaos Trougakos, Ioannis P. Kastritis, Efstathios Dimopoulos, Meletios A. Blood Cancer J Article Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and MGUS (n = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 (p = 0.009) and on day 50 (p = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders. Nature Publishing Group UK 2021-08-02 /pmc/articles/PMC8327056/ /pubmed/34341335 http://dx.doi.org/10.1038/s41408-021-00530-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Briasoulis, Alexandros
Gumeni, Sentiljana
Malandrakis, Panagiotis
Fotiou, Despina
Papanagnou, Eleni-Dimitra
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Kanellias, Nikolaos
Trougakos, Ioannis P.
Kastritis, Efstathios
Dimopoulos, Meletios A.
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
title The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
title_full The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
title_fullStr The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
title_full_unstemmed The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
title_short The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
title_sort neutralizing antibody response post covid-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327056/
https://www.ncbi.nlm.nih.gov/pubmed/34341335
http://dx.doi.org/10.1038/s41408-021-00530-3
work_keys_str_mv AT terposevangelos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT gavriatopouloumaria theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT ntanasisstathopoulosioannis theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT briasoulisalexandros theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT gumenisentiljana theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT malandrakispanagiotis theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT fotioudespina theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT papanagnouelenidimitra theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT migkoumagdalini theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT theodorakakoufoteini theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT roussoumaria theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT eleutherakispapaiakovouevangelos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT kanelliasnikolaos theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT trougakosioannisp theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT kastritisefstathios theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT dimopoulosmeletiosa theneutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT terposevangelos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT gavriatopouloumaria neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT ntanasisstathopoulosioannis neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT briasoulisalexandros neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT gumenisentiljana neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT malandrakispanagiotis neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT fotioudespina neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT papanagnouelenidimitra neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT migkoumagdalini neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT theodorakakoufoteini neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT roussoumaria neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT eleutherakispapaiakovouevangelos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT kanelliasnikolaos neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT trougakosioannisp neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT kastritisefstathios neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment
AT dimopoulosmeletiosa neutralizingantibodyresponsepostcovid19vaccinationinpatientswithmyelomaishighlydependentonthetypeofantimyelomatreatment